Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intravenous iron plus erythropoiesis-stimulating agents in chemotherapy-induced anemia
KCT0007849Phase 3Not yet recruiting
- Sponsor
- Korea Health Industry Development Institute
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iron in chemotherapy-induced anaemia (CIA), Functional iron deficiency (FID), sponsored by Korea Health Industry Development Institute. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
Iron
03
Conditions
chemotherapy-induced anaemia (CIA)Functional iron deficiency (FID)
Beyond the preview
Go deeper on KCT0007849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007849.